Article

Hydrogen Sulfide Improves Angiogenesis by Regulating the Transcription of pri-miR-126 in Diabetic Endothelial Cells

Wenlong Xue 1,2,3,†, Qingqing Zhang 1,2,3,†, Ying Chen 1,2,3 and Yichun Zhu 1,2,3,*

1 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China
2 Shanghai Key Laboratory of Bioactive Small Molecules, Fudan University, Shanghai 200032, China
3 Shanghai Key Laboratory of Clinical Geriatric Medicine, Fudan University, Shanghai 200032, China
* Correspondence: yczhu@shmu.edu.cn; Tel./Fax: +86-21-5423-7098
† These authors contributed equally to this study.

Abstract: Introduction: Diabetes mellitus results in high rates of cardiovascular disease, such as microcirculation disorder of the lower limbs, with angiogenesis impairment being the main factor. The endothelium functions as a barrier between blood and the vessel wall. Vascular endothelial cell dysfunction caused by hyperglycemia is the main factor leading to angiogenesis impairment. Hydrogen sulfide (H_{2}S) and miR-126-3p are known for their pro-angiogenesis effects; however, little is known about how H_{2}S regulates miR-126-3p to promote angiogenesis under high-glucose conditions. Objectives: The main objective of this research was to explore how H_{2}S regulates the miR-126-3p levels under high-glucose conditions. Methods: We evaluated the pro-angiogenesis effects of H_{2}S in the diabetic hindlimb of an ischemia mice model and in vivo Matrigel plugs. Two microRNA datasets were used to screen microRNAs regulated by both diabetes and H_{2}S. The mRNA and protein levels were detected through real-time PCR and Western blot, respectively. Immunofluorescent staining was also used to assess the capillary density and to evaluate the protein levels in vascular endothelial cells. Human umbilical vein endothelial cells (HUVECs) were used in in vitro experiments. A scratch wound-healing assay was applied to detect the migration ability of endothelial cells. Methylated DNA immunoprecipitation combined with real-time PCR was chosen to identify the DNA methylation level in the HUVECs. Results: Exogenous H_{2}S improved angiogenesis in diabetic mice. miR-126-3p was regulated by both diabetes and H_{2}S. Exogenous H_{2}S up-regulated the miR-126-3p level and recovered the migration rate of endothelial cells via down-regulating the DNMT1 protein level, which was increased by high glucose. Furthermore, DNMT1 upregulation in the HUVECs increased the methylation levels of the gene sequences upstream of miR-126-3p and then inhibited the transcription of primary-miR-126, thus decreasing the miR-126-3p level. CSE overexpression in the HUVECs rescued the miR-126-3p level, by decreasing the methylation level to improve migration. Conclusion: H_{2}S increases the miR-126-3p level through down-regulating the methylation level, by decreasing the DNMT1 protein level induced by high glucose, thus improving the angiogenesis originally impaired by high glucose.

Keywords: hydrogen sulfide; diabetes; angiogenesis; miR-126-3p

1. Introduction

Diabetes mellitus, a disorder of hyperglycemia caused by insulin resistance, has become a major global health pandemic [1]. In China, 110 million people suffered from diabetes in 2019, and this number is predicted to increase to 140 million by 2029 [2]. Diabetes mellitus results in high rates of cardiovascular disease. Peripheral limb ulceration and amputation arising from peripheral vascular disease are common complications of diabetes [3,4]. The endothelium functions as a barrier between the vessel wall and blood because it comprises a single cell layer lining the inner surface of the vascular lumen [5].
Endothelial cells perform multiple functions including regulation of cell adhesion, angiogenesis, inflammatory responses, vessel integrity, and vascular permeability [6]. Vascular endothelial cell dysfunction caused by hyperglycemia is the main factor leading to angiogenesis impairment [7]. Therefore, endothelial cells are the preferred target for improving angiogenesis. Although “therapeutic angiogenesis” is very challenging in the clinic, pro-angiogenic agents or gene therapy for “therapeutic angiogenesis” is still a priority scheme in patients with peripheral vascular disease.

Hydrogen sulfide (H\textsubscript{2}S) is the third gasotransmitter, after carbon monoxide and nitric oxide [8]. It is associated with several diseases; for instance, diabetic patients also have a lower H\textsubscript{2}S content in their plasma [9], and fasting blood glucose and H\textsubscript{2}S levels are negatively correlated in streptozotocin-induced diabetic rats [10]. Since Cai et al. first reported that H\textsubscript{2}S promotes angiogenesis in 2007 [11], H\textsubscript{2}S has become of increasing interest. Over the past decade, H\textsubscript{2}S has been discovered to improve skin wound healing in diabetic mice via anti-inflammation or antioxidants [12,13], particularly in modulating angiogenesis [14,15]. However, the pro-angiogenic mechanisms of H\textsubscript{2}S in diabetes remain to be further researched.

MicroRNAs are a class of non-coding RNAs, 18–22 nucleotides in length. They also regulate diabetic wound healing through pro-angiogenesis, e.g., miR-615-5p and miR-92a [16,17]. miR-126-3p is well-known for regulating angiogenesis in vascular endothelial cells [18–22]. miR-126 deficiency in mice leads to the formation of fragile and leaky vessels, aberrant endothelial tube hierarchy, and impaired endothelial cell migration and proliferation [18,23]. miR-126-3p can suppress its target gene PI3KR2, as well as SPRED1 and the like, to increase angiogenesis [24]. Interestingly, H\textsubscript{2}S also regulates miRNA transcription, and the crosstalk between H\textsubscript{2}S and microRNAs plays a crucial role in the pathophysiology of cardiovascular disease [25]. There are several works reporting that H\textsubscript{2}S can decrease the cardiomyocyte apoptosis induced by ischemia/reperfusion or can fight Parkinson’s disease by regulating microRNAs [26,27]. However, the relationship between H\textsubscript{2}S and microRNAs in regulating angiogenesis under high-glucose conditions remains unclear.

DNA methylation is an important epigenetic modification to regulate gene expression. DNA methyltransferase 1 (DNMT1) is one of the proteins maintaining DNA methylation. In colorectal cancer cells, DNMT1 regulates thymosin \( \beta 10 \) (TMSB10) expression to decrease tumor growth via maintaining the methylation of miR-152-3p [28]. In addition, DNMT1 acts as an anti-angiogenic protein [29,30]. The DNMT1 protein level is also connected with diabetes; for example, Zhang et al. found that DNMT1 protein is highly expressed in podocytes upon high-glucose treatment or in diabetic mice. Additionally, DNMT1 is a potential target for attenuating podocyte injury and diabetic nephropathy [31].

In our previous study, we found that H\textsubscript{2}S can rescue the miR-126-3p level by down-regulating the DNMT1 protein level in human umbilical vein endothelial cells (HUVECs) [32]. However, we remain unaware of how DNMT1 decreases miR-126-3p upon high-glucose treatment, and whether DNMT1 has an effect on blood flow recovery in diabetic hindlimb ischemia mice regulated by H\textsubscript{2}S. Herein, we aimed to explore the mechanism responsible for how H\textsubscript{2}S regulates the miR-126-3p level to improve the function of endothelial cells and to promote blood flow in diabetic hindlimb ischemia mice. In addition, HUVECs were also used in in vitro experiments.

2. Materials and Methods

2.1. Modeling of Type I Diabetic Mice

Wild-type C57BL/6 male mice (22–24 g) were obtained from the SLAC Laboratory (Shanghai, China), and the mice were maintained on a 12 h light/dark cycle with food and water available ad libitum. After acclimatization for two weeks, the mice were rendered diabetic by an intraperitoneal dose of 50 mg/kg of streptozotocin (Sigma-Aldrich, Saint Louis, MO, USA) for five consecutive days. After two weeks, blood glucose fasting for 4 h was detected via the tail of the animal using a portable glucometer (Johnson, New York, NY, USA). Mice with blood glucose levels of >13.8 mmol/L were categorized into the type I
Cells 2022, 11, 2651

3 of 17

diabetic mice group. The mice without STZ treatment were considered as the non-diabetic control group. In this study, we chose only male mice because estrogen directly modulates angiogenesis via effects on endothelial cells [33], which may disrupt the pro-angiogenesis effect of H₂S.

2.2. Murine Hindlimb Ischemia Model

The murine hindlimb ischemia model was set up as described previously [34]. Briefly, the C57BL/6 male mice were anesthetized with 1% pentobarbital sodium and placed on a heating pad (37 °C) to maintain body temperature. Then, the femoral artery was ligated and arteriotomy was performed without damaging the vein or nerve along the inner left hindlimb. Femoral artery ligation was not performed on the mice treated with a sham operation. The blood flow of the mice was monitored immediately using a MoorLDI2-2 laser Doppler imaging system (Moor Instruments, Devon, UK), to authenticate whether the model was successful. Only the mice that had been operated on successfully (the ratio of measurements in the ligated and non-ligated contralateral limbs was lower than 0.1) were used in the following experiment. NaHS (30 and 60 µmol/kg/day; Sigma, Saint Louis, MO, USA) was intraperitoneally injected every day for 14 days after ischemia [35]. Equivoluminal injections of saline solution served as the vehicle.

2.3. Immunofluorescence Assay

The gastrocnemius muscles were fixed in 4% paraformaldehyde and embedded in paraffin. For immunofluorescence staining, the embedded samples were sectioned, and these sections (4 µm) were deparaffinized and rehydrated using dimethylbenzene, graded ethanol, and water baths. Antigens were retrieved using sodium citrate buffer for 10 min at 95 °C. The sections were washed three times with PBS. Afterward, the sections were permeabilized with 0.01% Triton X-100 for 15 min. After washing three times with PBS, the sections were incubated in PBS containing 5% goat serum for 2 h to avoid non-specific protein binding. The sections were incubated with primary CD31 (mouse monoclonal antibody, 1:100; Novus, Littleton, CO, USA) and/or DNMT1 (rabbit polyclonal antibody, 1:100; Affinity, USA) overnight at 4 °C and further stained with Alexa Fluor® 488 anti-rabbit IgG (H+L) (1:100; CST, USA) and/or Alexa Fluor® 594 anti-mouse IgG (H+L) (1:100; CST, Topsfield, MA, USA) for 2 h at room temperature. After washing three times with PBS, 6-diamidino-2-phenylindole (DAPI; Beyotime, Shanghai, China) was used to visualize nuclear localization. Finally, the sections were immediately examined using a confocal microscope (ZEISS, Jena, Germany). The data were analyzed using ZEN 2010.

2.4. GEO Datasets of MicroRNA between the Diabetic and Control Groups

A high throughput dataset (accession number GSE140959) comparing the plasma microRNA expression profiles between control human (10 samples) and type II diabetic patients (10 samples) was downloaded from the GEO database [36]. These microarray data of GSE140959 were based on the platform GPL16384 (Affymetrix Multispecies miRNA-3 Array).

2.5. Data Preprocess and Differential MicroRNA Expression Analysis

To identify whether the microRNAs were significantly dysregulated in type II diabetes mellitus compared to the controls, differential microRNA expression analyses were conducted using the web analysis tool GEO2R. A volcano plot of the whole dataset was analyzed using the R-package ggplot2 (RStudio) and was generated using GraphPad Prism 7. An absolute log₂ (fold change) of >1.5 and a −log (p-Value) of >1.3 were considered as the criteria of significantly differently expressed genes.

2.6. Affymetrix MicroRNA Profiling

To detect the microRNA expression in primary human umbilical vein endothelial cells (HUVECs), the HUVECs were treated with NaHS (30 µmol/L) or the vehicle for
12 h in the first instance. Then, the RNA was isolated from the HUVECs using Trizol (Thermo, Waltham, MA, USA), in accordance with the protocol of the manufacturer. The microRNA expression was tested by an Affymetrix Gene Chip Expression Assay (Affymetrix, Santa Clara, CA, USA).

2.7. Reverse Transcription and Real-Time PCR

The RNA isolated from the tissues or HUVECs was measured by Nanodrop (Thermo, Waltham, MA, USA) to detect the concentration. Then, 1 µg of RNA was reverse transcribed using a FastKing Reverse Transcription Kit with gDNase (TIANGEN, Beijing, China). Gene amplification was achieved by real-time PCR using an SYBR Green Real-Time PCR Kit (Toyobo, Osaka, Japan). The reverse transcription of miR-126-3p was achieved by stem-loop RT-PCR. The sequences for the reverse and real-time PCR primers are summarized in Table S1. The 7300 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) was used for cDNA amplification and detection.

2.8. In Vivo Matrigel Plugs Analysis

Before Matrigel plugs analysis, the mice were divided into four groups: the non-diabetic control and vehicle group, diabetes and vehicle group, diabetes and NaHS (30 µmol/kg/day) group, and diabetes and NaHS (60 µmol/kg/day) group. On the first day, each mouse was subcutaneously injected with 500 µL of Matrigel plugs and was intraperitoneally injected saline solution or NaHS (30 and 60 µmol/kg/day) for seven consecutive days. The mice were euthanized after day 7, and the Matrigel plugs were harvested to detect the hemoglobin content and RNA levels, as described previously [37,38]. Briefly, the Matrigel plugs were recovered by dissection. The hemoglobin content was measured using the tetramethylbenzidine (TMB) method, and the values were normalized by the weight of the plugs.

2.9. Cell Culture

The HUVECs were purchased from ALLCELLS (Shanghai, China). The HUVECs from passages 4 to 7 were used in the experiment and were cultured in endothelial completed medium (ALLCELLS, Shanghai, China) at 37 °C in 5% CO2. The HUVECs were cultured in normal glucose medium (NG; 5.5 mmol/L of D-glucose) or high-glucose medium (HG; 33.3 mmol/L of D-glucose) for 48 h, and the L-glucose (27.8 mmol/L) contained in NG was used as the osmotic pressure control.

2.10. Cell Transfection and Lentivirus Infection

The antagomir NC and antagomir miR-126-3p were purchased from RIBOBIO Inc. (Guangzhou, China). The HUVECs were transfected in 150 µmol/L of antagomir miR-126-3p to inhibit the endogenous miR-126-3p level with Lipofectamine RNAiMAX Transfection Reagent (Thermo, Waltham, MA, USA), in accordance with the protocol of the manufacturer, and antagomir NC was used as the control. DNMT1-shRNA or CSE-GFP lentivirus was packaged by our laboratory according to a previous study [32]. After the lentivirus was prepared, the HUVECs were infected with lentivirus for 8 h, and 10 µg/mL of polybrene (Sigma, Saint Louis, MO, USA) was also added to increase the infection efficiency. Fresh complete medium was added to replace the lentivirus and polybrene-containing medium 8 h later. NC-shRNA and GFP-expressing lentivirus were used as the control for DNMT1-shRNA and CSE-GFP lentivirus, respectively. In addition, another CSE overexpression lentivirus (OE-CSE), without a GFP label, was used to avoid interference with the HSip-1 DA probes when detecting the cellular H2S level.

2.11. Measurements of the H2S Level

The endogenous H2S level in the HUVECs was measured using HSip-1 DA probes (DOJINDO, Kumamoto, Japan), in accordance with the protocol of the manufacturer [39]. Briefly, the HUVECs were washed with HBSS three times before being treated with the
2.12. Scratch Wound-Healing Assay

The HUVECs were grown to confluence (90%) in pre-coated six-well plates and starved for 12 h before the experiments for synchronous growth. Sterile pipette tips (1000 µL) were used to make scratch wounds, and the cells were washed three times with PBS to remove any floating cells. Then, the remaining cell sheets were cultured in basal medium (1% FBS) for another 24 h with different treatments. Images of the wounded area were taken immediately after the scratch and 24 h later. The wound areas were measured using ImageJ software.

2.13. Methylated DNA Immunoprecipitation (MeIP)

MeIP was performed as detailed previously [40]. Briefly, genomic DNA was isolated from the HUVECs in the first instance, and then genomic DNA was sonicated to obtain 300–100 bp fragments. The denatured DNA fragments (800 ng) were incubated with 5-mC antibody (1:50; Abcam, Waltham, MA, USA) for 2 h at 4 °C and washed three times with IP buffer (10 mM NaPO₄, 140 mM NaCl, 0.05% Triton X-100, pH 7.0), then Dynabeads (30 µL; Thermo, Waltham, MA, USA) were added into the mix with the DNA fragments and 5-mC antibody. The sample was then incubated in a rotating tube holder overnight at 4 °C. The DNA fragments bound with the 5-mC antibody were purified with Proteinase K and phenol/chloroform. The purified DNA fragments were then detected using real-time PCR to evaluate the DNA methylation level. The primer sequences for the real-PCR are listed in Table S1.

2.14. Ethics Approval and Consent to Participate

Our animal experimental procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH) of the United States and were approved by the Ethics Committee for Experimental Research of Fudan University, School of Basic Medical Sciences. IACUC Animal Project Numbers (APN): 20180302-026 and 20180302-045.

2.15. Statistical Analysis

The data were presented as mean ± SEM. All experiment data were analyzed using SPSS software and performed with GraphPad Prism 7 software. Two treatment groups were compared with student’s t-test, and three or more treatment groups were tested by one-way ANOVA followed by LSD tests. Probability value <0.05 was considered statistically significant.

3. Results

3.1. Exogenous H₂S Improved Angiogenesis in Diabetic Mice

To determine whether type I diabetic mice were created successfully, blood glucose fasting for 4 h was detected after the mice were treated with 50 mg/kg of STZ for five days. We chose diabetic mice with a blood glucose fasting that for 4 h was higher than 13.8 mmol/L for the next experiment (Figure 1A and Table S2), and these mice also showed lower body weight compared to the non-diabetic controls (Figure 1B and Table S3). The diabetic mice treated with NaHS (30 and 60 µmol/kg/day) for 14 days showed greater blood-flow recovery compared to the diabetic mice treated with the vehicle in hindlimb ischemia model (HLI) (Figure 1C,D). Hindlimb ischemia did not affect the gastrocnemius muscle weight in either the diabetic or non-diabetic mice (Figure S1A). However, the weight of
the non-ischemic gastrocnemius muscle decreased in the diabetic mice compared to the non-diabetic mice (Figure S1B). We also observed the capillary density through immunofluorescence, and our results indicated that the diabetic mice had lower capillary density in the ischemic gastrocnemius muscles compared to the non-diabetic control mice; however, exogenous H$_2$S improved the capillary density inhibition induced by diabetes (Figure 1E,F). Additionally, an in vivo Matrigel plug assay was also used to evaluate the pro-angiogenesis effect of H$_2$S. Our results showed that the hemoglobin content was inhibited in the Matrigel plugs of the diabetic mice compared to the non-diabetic mice and that NaHS treatment recovered the hemoglobin content in the diabetic mice (Figure 1G,H).

Figure 1. Exogenous H$_2$S promoted angiogenesis in vivo. (A) Blood glucose fasting in mice for 4 h before and after STZ (50 mg/kg/day) treatment every day for five days. (B) Body weight of the mice
before and after STZ (50 mg/kg/day) treatment every day for five days. (C,D) Representative blood flow images and statistical analysis with or without NaHS treatment in diabetic hindlimb ischemia mice and non-diabetic mice; n = 5–9. § vs. control and HLI and vehicle; †, # vs. STZ and HLI and vehicle. (E,F) Representative micrographs showing the capillary density stained with anti-mouse CD31 antibodies and statistical analysis with or without NaHS treatment in diabetic hindlimb ischemia mice and non-diabetic mice; bar = 100 µm, n = 4–6. (G,H) Representative Matrigel plug images and hemoglobin content in Matrigel plugs with or without NaHS treatment in diabetic and non-diabetic mice; n = 5–6.

3.2. MicroRNAs were Regulated by Both Diabetes and \( \text{H}_2\text{S} \)

In order to find out whether microRNAs are related to diabetes, we analyzed the plasma microRNA expression profiles between type II diabetic patients and healthy humans to identify whether microRNAs are significantly dysregulated in type II diabetes mellitus (Excel S1). We found that 22 microRNAs were dysregulated: 5 microRNAs were up-regulated and 17 were down-regulated (Figure 2A,B). Combined with the microRNAs regulated by \( \text{H}_2\text{S} \) in the HUVECs (Figure 2C,D), we found that six microRNAs were regulated by both diabetes and \( \text{H}_2\text{S} \), and one of them was up-regulated, while the others were downregulated (Figure 2E,F). miR-126-3p is one of the microRNAs that decreased in the plasma of the diabetic patients but was up-regulated by \( \text{H}_2\text{S} \).

Figure 2. Cont.
Figure 2. The microRNAs regulated by diabetes and exogenous H$_2$S. (A) Volcano plot of the expressed microRNAs in the plasma between the control and diabetic patients; n = 10. (B) Heat map of the expression levels of 22 dysregulated microRNAs. Each row represents a microRNA and each column represents a sample. (C) Heat map of the microRNA expression levels up-regulated by NaHS (30 µmol/L). (D) Heat map of the microRNA expression levels down-regulated by NaHS (30 µmol/L). (E) Venn diagram of the significantly upregulated or downregulated microRNAs between diabetes-induced dysregulated microRNAs and H$_2$S-regulated microRNAs. (F) Statistical analysis of the dysregulated microRNA expression in plasma induced by diabetes and also regulated by H$_2$S; n = 10.

3.3. Exogenous H$_2$S Regulated the miR-126-3p and DNMT1 Levels in the Ischemic Gastrocnemius Muscles of Diabetic Mice

To confirm whether the miR-126-3p level decreased in the diabetic mice, we detected the miR-126-3p level in the gastrocnemius muscles. Our results indicated that the miR-126-3p level in the gastrocnemius muscles decreased in the diabetic mice compared to the non-diabetic mice (Figure 3A). Furthermore, NaHS treatment partly rescued the miR-126-3p level in the ischemic gastrocnemius muscles (Figure 3B). So, to explore how H$_2$S regulates the miR-126-3p level, we analyzed the base sequence around miR-126-3p through MethPrimer software and found that there are several CpG islands upstream of miR-126-3p (Figure 3C), many of which affected the transcription of primary miR-126 (pri-miR-126). As DNMT1 is one of the significant proteins regulating DNA methylation, we detected the DNMT1 protein level in the HUVECs and ischemic gastrocnemius muscles. Exogenous H$_2$S rescued the DNMT1 protein level in the HUVECs induced by high glucose (Figure 3D). Furthermore, both the DNMT1 mRNA (Figure 3E) and protein levels (Figure 3F,G) increased in the ischemic gastrocnemius muscles, and NaHS treatment rescued this phenomenon. Meanwhile, ischemia treatment had no effect on the expression of DNMT1 (Figure 3F,G).
Figure 3. Exogenous H₂S enhanced the miR-126-3p level and decreased the DNMT1 level in the gastrocnemius muscles of diabetic mice. (A) miR-126-3p levels in diabetic muscles compared to the non-diabetic controls; n = 5. (B) miR-126-3p levels in the ischemia muscles of diabetic mice with NaHS (30 and 60 µmol/kg/day) treatment compared to the non-diabetic controls; n = 5~7. (C) Schematic illustration of CpG islands before the gene of miR-126-3p. (D) DNMT1 protein level of HUVECs with NaHS (30 µmol/L) treatment under high-glucose conditions; n = 3. (E) DNMT1 mRNA level in the ischemia muscles of diabetic mice with NaHS (30 and 60 µmol/kg/day) treatment compared to the non-diabetic controls; n = 5~7. (F, G) Representative micrographs showing DNMT1 with rabbit antibodies against DNMT1 and statistical analysis of the DNMT1 protein expression in the gastrocnemius muscles of diabetic hindlimb ischemia mice compared to non-diabetic mice with or without NaHS (30 µmol/kg/day) treatment; bar = 50 µm, n = 4~6.
3.4. miR-126-3p Was Downstream of DNMT1 to Regulate Angiogenesis in Endothelial Cells

Considering that the progress of angiogenesis mainly occurs in endothelial cells, we detected the DNMT1 protein level in the endothelial cells of the ischemic gastrocnemius muscles through immunofluorescence. The results indicated that exogenous H$_2$S decreased the DNMT1 protein level in the endothelial cells that were up-regulated (induced by diabetes) (Figure 4A,B). The Matrigel plug model is the most classic model used to evaluate the effect of angiogenesis, and the main cells that grow into Matrigel plugs are endothelial cells. Thus, we detected the DNMT1 and miR-126-3p levels in the Matrigel plugs. The DNMT1 mRNA level in the Matrigel plugs was in accordance with the protein levels in the endothelial cells of the ischemic gastrocnemius muscles (Figure 4C). Moreover, exogenous H$_2$S also increases the miR-126-3p level in the Matrigel plugs, which was decreased by diabetes (Figure 4D). Moreover, to confirm whether DNMT1 and miR-126-3p take part in angiogenesis under high-glucose conditions, we knocked down DNMT1 and miR-126-3p. The inhibition efficiency of the DNMT1 protein and miR-126-3p levels were approximately 84% and 30%, respectively (Figure S2A–C). Our results demonstrated that high-glucose-inhibited wound healing (Figure 4E,F), and DNMT1 knocked down under high-glucose conditions improved the wound healing of endothelial cells (Figure 4E,G). However, the effect of pro-migration was blocked, while DNMT1 and miR-126-3p were knocked down at the same time (Figure 4E,G).

Figure 4. Exogenous H$_2$S enhanced the miR-126-3p level and decreased the DNMT1 level in endothelial cells. (A) Representative micrographs showing the endothelial cells in the gastrocnemius muscles.
Exogenous H$_2$S enhanced the miR-126-3p level and decreased the DNMT1 level in endothelial cells. (A) Representative micrographs showing the endothelial cells in the gastrocnemius muscles, 14 days after hindlimb ischemia surgery, stained with mouse antibodies against CD31 and rabbit antibodies against DNMT1; bar = 50 µm. (B) Statistical analysis of the DNMT1 protein expression in the endothelial cells of the gastrocnemius muscles with or without NaHS (30 and 60 µmol/kg/day) treatment; n = 5–6. (C) DNMT1 mRNA level in Matrigel plugs with or without NaHS (30 and 60 µmol/kg/day) treatment; n = 5–6. (D) miR-126-3p level in Matrigel plugs with or without NaHS (30 and 60 µmol/kg/day) treatment; n = 5–6. (E) Representative micrographs of HUVEC scratch wound healing with DNMT1 and miR-126-3p knocked down under high-glucose conditions; bar = 500 µm. (F) Statistical analysis of HUVEC scratch wound healing treated with high glucose; n = 4. (G) Statistical analysis of HUVEC scratch wound healing with DNMT1 and miR-126-3p knocked down under high-glucose conditions; n = 4.

3.5. CSE Overexpression Increased the Transcription of pri-miR-126 under High-Glucose Conditions

CSE is the main synthetase in the cardiovascular system, so we enhanced the endogenous H$_2$S level through overexpression of the CSE protein. We overexpressed the DNMT1 protein level to simulate the effects induced by high glucose and rescued via CSE overexpression. The DNMT1 and CSE overexpression efficiencies were evaluated by Western blot, and they were severally up-regulated by 1.4- and 6-fold, respectively (Figure S2D–F). Our results showed that CSE overexpression increases the cellular H$_2$S level in the HUVECs, which was decreased by high-glucose treatment (Figure 5A,B). MeIP combined with real-time PCR was used to detect the DNA methylation levels, according to the protocol (Figure 5C). The DNA methylation level was increased under high-glucose conditions (Figure 5D). CSE overexpression decreased the DNA methylation level induced by high glucose. However, the effects of CSE were blocked, while DNMT1 was overexpressed at the same time (Figure 5D). Considering that the DNMT1 protein level was up-regulated by high glucose, we overexpressed the DNMT1 protein level to simulate this effect. We found that the pri-miR-126 and miR-126-3p levels declined, while DNMT1 was overexpressed (Figure 5E,F).
Figure 5. DNMT1 overexpression decreased pri-miR-126 and miR-126-3p levels in endothelial cells. (A) Representative micrographs showing the endogenous H$_2$S in HUVECs with or without CSE overexpression under high-glucose conditions; bar = 50 µm. (B) Statistical analysis of fluorescence intensity of endogenous H$_2$S; n = 3. (C) Schematic illustration of methylated DNA immunoprecipitation. (D) Statistical analysis of methylated DNA immunoprecipitation; n = 3. (E) pri-miR-126 levels in HUVECs with DNMT1 overexpression; n = 3. (F) miR-126-3p levels in HUVECs with DNMT1 overexpression; n = 4.

3.6. CSE Overexpression Rescued the miR-126-3p Level through Regulating DNMT1 Expression

To determine whether endogenous H$_2$S improves the cell migration impaired by high glucose, we simultaneously overexpressed the CSE and DNMT1 protein levels. Our results exhibited that CSE partially rescued the migration inhibited by high glucose, and this effect was blocked while DNMT1 was overexpressed (Figure 6A,B). Likewise, high-glucose-induced downregulation in pri-miR-126 and miR-126-3p was rescued with CSE overexpression, and these effects were blunted in HUVECs while DNMT1 was overexpressed (Figure 6C,D).
Figure 6. Upregulation of endogenous H2S increased the transcription of pri-miR-126 via decreasing the DNMT1 level in endothelial cells. (A,B) Representative images of scratch wound healing in HUVECs with CSE or DNMT1 overexpression (A) and statistical analysis (B); bar = 500 µm, n = 3. (C) pri-miR-126 level in HUVECs with CSE or DNMT1 overexpression; n = 3. (D) miR-126-3p level in HUVECs with CSE or DNMT1 overexpression; n = 3.

4. Discussion

Diabetes mellitus is one of the primary threats to human health. It induces microvascular complications caused by vascular endothelial cell dysfunction. Gangrene and diabetic retinopathy are two of the most representative diseases resulting from diabetes mellitus, and both of these diseases are induced by abnormal angiogenesis. The low ability of angiogenesis ulteriorly causes microcirculation disorders in the lower limbs. As a pro-angiogenesis gasotransmitter, the H2S level is lower in the plasma of individuals with diabetes mellitus [41], and it is likely to improve angiogenesis through regulating vascular endothelial cells in hyperglycemia.

The hindlimb ischemia model is a classic in vivo model used to evaluate the function of angiogenesis [42]. Our results displayed that H2S improved the blood flow in hindlimb ischemic diabetic mice. Considering that capillaries play an important role in angiogenesis, we detected and found that H2S increased the capillary density. We also assessed the pro-angiogenesis effects of H2S through a Matrigel plug assay. Our results suggest that H2S rescues the hemoglobin in Matrigel plugs down-regulated by hyperglycemia, which is consistent with the previous study [43]. Although H2S improved the blood supply via promoting angiogenesis in diabetic mice, little is known about the mechanism by which this occurs.

MicroRNAs are a class of endogenous small non-coding RNAs, which can induce mRNA degradation and translational repression via interaction with the 3′ UTR, 5′ UTR,
or CDS of the target mRNAs [44]. Given that abnormally expressed microRNAs play a critical role in the pathogenesis of microvascular complications [45], we focused on whether microRNAs participate in the angiogenesis regulated by H₂S. We found that miR-126-3p is regulated by both diabetes and H₂S, by analyzing two sets of microRNA array data. Zhang et al. reported that miR-126-3p could be a biomarker of diabetes mellitus, showing significantly reduced expression in diabetic plasma [46], which further indicates that the microRNA array data from GEO databases are reliable. In diabetic mice, we also confirmed that the miR-126-3p level was down-regulated when induced by STZ, and exogenous H₂S improved the miR-126-3p level in the muscle. Considering the data of plasma microRNA from patients with type II diabetes, we thought the high-fat model of type II diabetes is indeed more relevant. However, it would be better if we measured the microRNA levels in mouse plasma.

DNA methylation, an important epigenetic modification, regulates a number of biological processes. Ohad Glaich reported that DNA methylation can regulate the generation of microRNAs [47]. Jyotirmaya Behera et al. found that H₂S decreases DNMT activity and then alleviates HHcy-induced hypermethylation [48]. We reported the phenomenon that H₂S can rescue the miR-126-3p level via inhibiting DNMT1 expression in the HUVECs [32], and exogenous H₂S reduces the DNMT1 mRNA and protein levels in muscle-induced hyperexpression. Vascular endothelial cells are the main cells participating in angiogenesis [49]. We detected the DNMT1 protein level in CD31⁺ cells via immunofluorescent staining, and we found that H₂S decreased the DNMT1 levels in vascular endothelial cells up-regulated by hyperglycemia. However, it is difficult for us to isolate vascular endothelial cells to detect the DNMT1 mRNA and miR-126-3p levels in ischemic muscles; thus, we examined the endothelial cells in Matrigel plugs, where endothelial cells are newly formed [32]. Exogenous H₂S also recovered the DNMT1 mRNA and miR-126-3p levels in endothelial cells under high-glucose conditions. It is worth noting that several figures, such as Figure 3B,E, showed that increased H₂S reverses any beneficial effects. In fact, there is no significant difference between 30 and 60 µmol/kg/day of NaHS in diabetic mice because of the large dispersion in the data. H₂S ameliorates angiogenesis in diabetic mice with no dose-dependence, but it is unknown whether a higher concentration of H₂S would show beneficial effects. Moreover, the number of CD31 positive cells and the content of hemoglobin in the Matrigel plugs are usually used to evaluate angiogenesis. In this study, we only detect the hemoglobin content in the Matrigel plugs. We believe that it will be more convincing if we measure the CD31 positive cells via HE staining or immunohistochemical staining with CD31 antibody at the same time. Furthermore, we also confirmed that miR-126-3p mediates the inhibitory effect of DNMT1 on endothelial cell migration. Nevertheless, we still do not know how DNMT1 mediates the process of H₂S regulating the miR-126-3p level under high-glucose conditions. In addition, we do not know how H₂S decreases the DNMT1 mRNA level. mRNA production is regulated by transcription factors and transcription repressors, and H₂S can regulate the expression of transcription factors [50,51]. Considering H₂S decreases the DNMT1 protein level via limiting its mRNA, we think H₂S regulates DNMT1 at the transcriptional level.

CpG islands or residues, the significant sites in which methylation occurs, are located in the host gene, intronic miRNA promoter, and miRNA gene promoters. DNA methylation affects microRNA expression via reducing these promoters’ activities [52]. We further analyzed the features of the miR-126-3p sequence using MethPrimer software, and found that miR-126-3p and pri-miR-126 are located in primary EGFL7 transcription. Additionally, several CpG islands were found upstream of pri-miR-126, indicating that miR-126-3p expression may be affected by DNA methylation. To confirm the degree of DNA methylation upstream of pri-miR-126, we used DNA MeIP combined with real-time PCR. Here, we overexpressed DNMT1 expression to simulate the effects of high glucose on endothelial cells. The results indicated that high glucose and DNMT1 overexpression increased the DNA methylation level in the HUVECs, in accordance with the previous study [53]. Moreover, the levels of pri-miR-126 and miR-126 were inhibited with DNMT1
overexpression. We also found that CSE overexpression inhibited the DNA methylation level induced by high glucose and rescued pri-miR-126 transcription and miR-126-3p production. However, the effects of CSE were blocked while DNMT1 was overexpressed. In addition, DNMT1 mediated the endothelial cell migration regulated by H$_2$S.

The novelty is that we first demonstrated that H$_2$S improves angiogenesis, by regulating the transcription of the pri-miR-126 and miR-126-3p levels in diabetic endothelial cells, via down-regulating high-glucose-mediated DNMT1 upregulation.

5. Conclusions

In conclusion, this study focused on the role of H$_2$S in the improvement of angiogenesis in diabetic mice via down-regulating the DNA methylation level. DNMT1 plays a critical role during the angiogenesis process in diabetic mice. Our findings provide new insights into the role of H$_2$S in regulating miR-126-3p under high-glucose conditions and suggest a new target for ischemic therapy in diabetes mellitus.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11172651/s1, Figure S1: Muscle weight of the diabetic mice; Figure S2: The efficiency of manipulating the DNMT1, miR-126-3p, and CSE expression in endothelial cells; Table S1: Sequences for the reverse and real-time PCR primers; Table S2: Blood glucose with or without STZ treatment; Table S3: Body weight with or without STZ treatment; Excel S1: miRNAs expression in plasma between healthy controls and diabetes mellitus.

Author Contributions: W.X. and Y.Z. designed the research. W.X., Q.Z. and Y.C. performed the experiments. W.X. and Q.Z. analyzed the experimental data and interpreted the experimental results. W.X. drafted the manuscript. Y.Z. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by: (1) National Natural Science Foundation of China: 31830042 and 81870212; (2) Macau Science and Technology Development Fund: FDCT 0007/2019/AKP; (3) the Science and Technology Commission of Shanghai Municipality: 21140904200 and 21410761000; (4) the funding of Innovative research team of high-level local universities in Shanghai; (5) a Key Laboratory Program of the Shanghai Municipal Education Commission: ZDSYS14005.

Institutional Review Board Statement: The animal study protocol was approved by the Ethics Committee of Fudan University School of Basic Medical Sciences (IACUC; Protocol Code 20180302-026, Approval Data: 2 March 2018).

Informed Consent Statement: Not applicable.

Data Availability Statement: All supporting data and materials are available online.

Acknowledgments: This work was supported by the National Natural Science Foundation of China (31830042 and 81870212 to Yi-chun Zhu), the Macau Science and Technology Development Fund (FDCT 0007/2019/AKP), the Science and Technology Commission of Shanghai Municipality (21140904200, 21410761000 to Yi-chun Zhu), and the funding of innovative research team of high-level local universities in Shanghai, a Key Laboratory Program of the Shanghai Municipal Education Commission (ZDSYS14005 to Yi-chun Zhu).

Conflicts of Interest: The authors declare no competing interest.

References
1. Lee, J.; Hale, N. Evidence and Implications of the Affordable Care Act for Racial/Ethnic Disparities in Diabetes Health during and Beyond the Pandemic. Popul. Health Manag. 2022, 25, 235–243. [CrossRef] [PubMed]
2. Ma, R.C.W. Epidemiology of diabetes and diabetic complications in China. Diabetologia 2018, 61, 1249–1260. [CrossRef] [PubMed]
3. Willyard, C. Limb-saving medicines sought to prevent amputations. Nat. Med. 2012, 18, 328. [CrossRef] [PubMed]
4. Jonasson, J.M.; Ye, W.; Sparén, P.; Apelqvist, J.; Nyrén, O.; Brismar, K. Risks of Nontraumatic Lower-Extremity Amputations in Patients with Type 1 Diabetes: A population-based cohort study in Sweden. Diabetes Care 2008, 31, 1536–1540. [CrossRef] [PubMed]
5. Sumpio, B.E.; Riley, J.T.; Dardik, A. Cells in focus: Endothelial cell. Int. J. Biochem. Cell Biol. 2002, 34, 1508–1512. [CrossRef]
6. Kaur, R.; Kaur, M.; Singh, J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies. *Cardiovasc. Diabetol*. **2018**, *17*, 1–17. [CrossRef]

7. Dinh, T.; Scovell, S.; Veyes, A. Review: Peripheral Arterial Disease and Diabetes: A Clinical Update. *Int. J. Low. Extremity Wounds* **2009**, *8*, 75–81. [CrossRef]

8. Łowicka, E.; Beltowska, J. Hydrogen sulfide (H2S)—the third gas of interest for pharmacologists. *Pharmacol. Rep.* **2007**, *59*, 4–24.

9. Suzuki, K.; Sagara, M.; Aoki, C.; Tanaka, S.; Aso, Y. Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes. *Intern. Med.* **2017**, *56*, 17–21. [CrossRef]

10. Dutta, M.; Biswas, U.K.; Chakraborty, R.; Banerjee, P.; Raychaudhuri, U.; Kumar, A. Evaluation of plasma H2S levels and H2S synthesis in streptozotocin induced Type-2 diabetes—an experimental study based on Swietenia macrophylla seeds. *Asian Pac. J. Trop. Biomed.* **2014**, *4*, S483–S487. [CrossRef]

11. Cai, W.-J.; Wang, M.-J.; Moore, P.K.; Jin, H.-M.; Yao, T.; Zhu, Y.-C. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. *Cardiovasc. Res.* **2007**, *76*, 29–40. [CrossRef] [PubMed]

12. Wang, G.; Li, W.; Chen, Q.; Jiang, Y.; Lu, X.; Zhao, X. Hydrogen sulfide accelerates wound healing in diabetic rats. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 5097–5104. [PubMed]

13. Zhao, H.; Lu, S.; Chai, J.; Zhang, Y.; Ma, X.; Chen, J.; Guan, Q.; Wan, M.; Liu, Y. Hydrogen sulfide improves diabetic wound healing in ob/ob mice via attenuating inflammation. *J. Diabetes Its Complicat.* **2017**, *31*, 1363–1369. [CrossRef] [PubMed]

14. Wang, G.-G.; Li, W. Hydrogen sulfide improves vessel formation of the ischemic adductor muscle and wound healing in diabetic db/db mice. *Iran. J. Basic Med. Sci.* **2019**, *22*, 1192–1197. [CrossRef] [PubMed]

15. Liu, F.; Chen, D.-D.; Sun, X.; Xie, H.-H.; Yuan, H.; Jia, W.; Chen, A.F. Hydrogen Sulfide Improves Wound Healing via Restoration of Endothelial Progenitor Cell Functions and Activation of Angiopoietin-1 in Type 2 Diabetes. *Diabetes* **2014**, *63*, 1763–1778. [CrossRef]

16. Zhou, Y.; Li, X.-H.; Xue, W.-L.; Jin, S.; Li, M.-Y.; Zhang, C.-C.; Yu, B.; Zhu, L.; Liang, K.; Chen, M.Y.; et al. YB-1 Recruits Drosha to Promote Splicing of pri-miR-192 to Mediate the Proangiogenic Effects of H2S. *Antioxidants Redox Signal.* **2022**, *36*, 760–783. [CrossRef]

17. Icli, B.; Wu, W.; Ozdemir, D.; Li, H.; Cheng, H.S.; Haemmig, S.; Liu, X.; Giatsidis, G.; Avci, S.N.; Lee, N.; et al. MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells. *Arter. Thromb. Vasc. Biol.* **2019**, *39*, 1458–1474. [CrossRef]

18. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The Endothelial-Specific MicroRNA miR-126 Governs Vascular Integrity and Angiogenesis. *Dev. Cell* **2008**, *15*, 261–271. [CrossRef] [PubMed]

19. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. *J. Mol. Cell. Cardiol.* **2016**, *67*, 47–55. [CrossRef] [PubMed]

20. Bassand, K.; Metzinger, L.; Naïm, M.; Mouhoubi, N.; Haddad, O.; Assoun, V.; Zaidi, N.; Sainte-Catherine, O.; But, A.; Guyot, E.; et al. miR-126-3p is essential for CXCL12-induced angiogenesis. *J. Cell. Mol. Med.* **2021**, *25*, 6032–6045. [CrossRef]

21. Zhou, Q.; Anderson, C.; Hanus, J.; Zhao, F.; Ma, J.; Yoshimura, A.; Wang, S. Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis. *Mol. Ther.* **2016**, *24*, 1823–1835. [CrossRef] [PubMed]

22. Gao, H.; Peng, C.; Wu, L.; Gao, S.; Wang, Z.; Dai, L.; Wu, H. Yiqi-Huoxue granule promotes angiogenesis of ischemic myocardium through miR-126/P13K /Akt endothelial axis cells. *Phytomedicine* **2021**, *92*, 153713. [CrossRef]

23. Kuhnert, F.; Mancuso, M.R.; Hampton, J.; Stankunas, K.; Asano, T.; Chen, C.-Z.; Kuo, C.J. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA-126. *Development* **2008**, *135*, 3989–3993. [CrossRef] [PubMed]

24. Cao, W.J.; Rosenblat, J.D.; Roth, N.C.; Kuliszewski, M.A.; Matkar, P.N.; Rudenko, D.; Liao, C.; Lee, P.J.; Leong-Poi, H. Therapeutic Angiogenesis by Ultrasound-Mediated MicroRNA-126-3p Delivery. *Arter. Thromb. Vasc. Biol.* **2015**, *35*, 2401–2411. [CrossRef] [PubMed]

25. Hackfort, B.T.; Mishra, P.K. Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases. *Am. J. Physiol. Heart Circ. Physiol.* **2016**, *310*, H802–H812. [CrossRef] [PubMed]

26. Ren, L.; Wang, Q.; Chen, Y.; Ma, Y.; Wang, D. Involvement of MicroRNA-133a in the Protective Effect of Hydrogen Sulfide against Ischemia/Reperfusion-Induced Endoplasmic Reticulum Stress and Cardiomyocyte Apoptosis. *Pharmacology* **2018**, *103*, 1–9. [CrossRef]

27. Liu, Y.; Liao, S.; Quan, H.; Lin, Y.; Li, Y.; Yang, Q. Involvement of microRNA-133a-5p in the Protective Effects of Hydrogen Sulfide Against Parkinson’s Disease. *Cell. Physiol. Biochem.* **2016**, *40*, 18–26. [CrossRef]

28. Wang, C.; Ma, X.; Zhang, J.; Jia, X.; Huang, M. DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells. *IUBMB Life* **2020**, *72*, 2432–2443. [CrossRef]

29. Balakrishnan, A.; Guruprasad, K.P.; Satyamoorthy, K.; Joshi, M.B. Interleukin-6 determines protein stabilization of DNA methyltransferase and alters DNA promoter methylation of genes associated with insulin signaling and angiogenesis. *Lab. Investig.* **2018**, *98*, 1143–1158. [CrossRef]

30. Zhao, J.; Yang, S.; Shu, B.; Chen, L.; Yang, R.; Xu, Y.; Xie, J.; Liu, X.; Qi, S. Transient High Glucose Causes Persistent Vascular Dysfunction and Delayed Wound Healing by the DNMT1-Mediated Ang-1/NF-kappaB Pathway. *J. Investig. Dermatol.* **2020**, *141*, 1573–1584. [CrossRef]

31. Zhang, L.; Zhang, Q.; Liu, S.; Chen, Y.; Li, R.; Lin, T.; Yu, C.; Zhang, H.; Huang, Z.; Zhao, X.; et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. *Kidney Int.* **2017**, *92*, 140–153. [CrossRef] [PubMed]
32. Xue, W.-L.; Chen, R.-Q.; Zhang, Q.-Q.; Li, X.-H.; Cao, L.; Li, M.-Y.; Li, Y.; Lin, G.; Chen, Y.; Wang, M.-J.; et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. *Am. J. Physiol.Cell Physiol.* 2020, 318, C857–C869. [CrossRef] [PubMed]

33. Losordo, D.W.; Isner, J.M. Estrogen and angiogenesis: A review. *Arter. Thromb. Vasc. Biol.* 2001, 21, 6–12. [CrossRef] [PubMed]

34. Niiyama, H.; Huang, N.; Rollins, M.D.; Cooke, J.F. Murine Model of Hindlimb Ischemia. *J. Vis. Exp.* 2009, 37, e935. [CrossRef] [PubMed]

35. Whitman, M.; Moore, P.K. Hydrogen sulfide and the vasculature: A novel vasculoprotective entity and regulator of nitric oxide bioavailability? *J. Cell. Mol. Med.* 2009, 13, 488–507. [CrossRef]

36. Smit-McBride, Z.; Nguyen, A.T.; Yu, A.K.; Modjtahedi, S.P.; Hunter, A.A.; Rashid, S.; Moisseiev, E.; Morse, L.S. Unique molecular signatures of microRNAs in ocular fluids and plasma in diabetic retinopathy. *PLoS ONE* 2020, 15, e0235541. [CrossRef]

37. Bonauer, A.; Carmona, G.; Iwasaki, M.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; et al. MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice. *Science* 2009, 324, 1710–1713. [CrossRef]

38. Jiang, L.; Jia, M.; Wei, X.; Guo, J.; Hao, S.; Mei, A.; Zhi, X.; Wang, X.; Li, Q.; Jin, J.; et al. Bach1-induced suppression of angiogenesis in a mouse model of hind-limb ischemia. *Nat. Protoc.* 2009, 4, 1737–1748. [CrossRef]

39. Coletta, C.; Módis, K.; Szczesny, B.; Brunýanszki, A.; Oláh, G.; Rios, E.C.S.; Yanagi, K.; Ahmad, A.; Papapetropoulos, A.; Szabo, C. Regulation of Vascular Tone, Angiogenesis and Cellular Bioenergetics by the 3-Mercaptopyruvate Sulfitotransferase/H2S Pathway: Functional Impairment by Hyperglycemia and Restoration by DL-alpha-Lipoic Acid. *Mol. Med.* 2015, 21, 1–14. [CrossRef]

40. Thu, K.L.; Vucic, E.A.; Kennett, J.Y.; Heryet, C.; Brown, C.; Lam, W.L.; Wilson, I.M. Methylated DNA Immunoprecipitation. *J. Vis. Exp.* 2009, e935. [CrossRef]

41. Whiteman, M.; Gooding, K.M.; Whatmore, J.L.; Ball, C.I.; Mawson, D.; Skinner, K.; Tooke, J.E.; Shore, A.C. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. *Diabeticologia* 2010, 53, 1722–1726. [CrossRef] [PubMed]

42. Limbourg, A.; Korff, T.; Napp, L.C.; Schaper, W.; Drexler, H.; Limbourg, F. Evaluation of postnatal arteriogenesis and angiogenesis: Development of a Highly Selective Fluorescence Probe for Hydrogen Sulfide. *J. Am. Chem. Soc.* 2011, 133, 18003–18005. [CrossRef]

43. Bonauer, A.; Carmona, G.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; et al. MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice. *Science* 2009, 324, 1710–1713. [CrossRef]

44. Rennie, W.; Kanoria, R.; Liu, C.; Mallick, B.; Long, D.; Wolenc, A.; Carmack, C.S.; Lu, J.; Ding, Y. STarMirDB: A database of microRNA binding sites. *RNA Biol.* 2016, 13, 554–560. [CrossRef]

45. Zhang, T.; Lv, C.; Li, L.; Chen, S.; Liu, S.; Wang, C.; Su, B. Plasma miR-126 Is a Potential Biomarker for Early Prediction of Type 2 Diabetes Mellitus in Susceptible Individuals. *BioMed Res. Int.* 2013, 2013, 761617. [CrossRef]

46. Glaiach, O.; Parikh, S.; Bell, R.E.; Mekahel, K.; Donyo, M.; Leader, Y.; Shayevtich, R.; Sheinboim, D.; Yannai, S.; Hollander, D.; et al. DNA methylation directs microRNA biogenesis in mammalian cells. *Nat. Commun.* 2019, 10, 5657. [CrossRef] [PubMed]

47. Glaich, O.; Parikh, S.; Bell, R.E.; Mekahel, K.; Donyo, M.; Leader, Y.; Shayevtich, R.; Sheinboim, D.; Yannai, S.; Hollander, D.; et al. DNA methylation directs microRNA biogenesis in mammalian cells. *Nat. Commun.* 2019, 10, 5657. [CrossRef] [PubMed]

48. Behera, J.; George, A.K.; Voor, M.J.; Tyagi, S.C.; Tyagi, N. Hydrogen sulfide epigenetically mitigates bone loss through OPG/RANKL regulation during hypero-mocysteinemia in mice. *Bone* 2018, 114, 90–108. [CrossRef]

49. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial Cell Migration During Angiogenesis. *Circ. Res.* 2007, 100, 782–794. [CrossRef]

50. de Mello, A.H.; Liu, T.; Garofalo, R.P.; Casola, A. Hydrogen Sulphide Donor GYY4137 Rescues NRF2 Activation in Respiratory Syncytial Virus Infection. *Antioxidants* 2022, 11, 1410. [CrossRef]

51. Li, S.; Yang, G. Hydrogen Sulphide Maintains Mitochondrial DNA Replication via Demethylation of TFAM. *Antioxidants Redox Signal.* 2015, 23, 630–642. [CrossRef] [PubMed]

52. Matsuyama, H.; Suzuki, H.I. Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis. *Int. J. Mol. Sci.* 2019, 21, 132. [CrossRef] [PubMed]

53. Heuslein, J.L.; Gorick, C.M.; Song, J.; Price, R.J. DNA Methyltransferase 1–Dependent DNA Hypermethylation Constrains Arteriogenesis by Augmenting Shear Stress Set Point. *J. Am. Heart Assoc.* 2017, 6, e007673. [CrossRef] [PubMed]